Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dinutuximab Added to Intensive Multimodal Therapy for Newly Diagnosed High-Risk Neuroblastoma
NCT06172296Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2024
- Primary completion
- Dec 2029
- Countries
- 5
01
Overview
A Phase 3 trial of dinutuximab in neuroblastoma, sponsored by National Cancer Institute. Started Apr 2024; status: recruiting.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT06172296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06172296.